Cara gains after analgesic readout

Cara Therapeutics Inc. (NASDAQ:CARA) added $1.62 (10%) to $18.06 Wednesday after IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III

Read the full 248 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE